{"blog_title":"\u6c17\u306b\u306a\u3063\u305f\u7279\u8a31\u306e\u8a71\u984c -Patent Topics Explorer-","html":"<iframe src=\"https://hatenablog-parts.com/embed?url=https%3A%2F%2Fwww.patent-topics-explorer.com%2Fentry%2F2022%2F01%2F08%2F005418\" title=\"\u7c73\u56fd: \u30d5\u30a1\u30a4\u30b6\u30fc\u793e\u3068Allele\u793e\u304cCOVID-19\u30ef\u30af\u30c1\u30f3\u958b\u767a\u3067\u306e\u30ea\u30b5\u30fc\u30c1\u30c4\u30fc\u30eb\u4f7f\u7528\u306b\u304a\u3051\u308b\u7279\u8a31\u4fc2\u4e89\u3067\u548c\u89e3 - \u6c17\u306b\u306a\u3063\u305f\u7279\u8a31\u306e\u8a71\u984c -Patent Topics Explorer-\" class=\"embed-card embed-blogcard\" scrolling=\"no\" frameborder=\"0\" style=\"display: block; width: 100%; height: 190px; max-width: 500px; margin: 10px 0px;\"></iframe>","type":"rich","image_url":"https://cdn.user.blog.st-hatena.com/default_entry_og_image/23666471/164113008024266","height":"190","provider_url":"https://hatena.blog","version":"1.0","provider_name":"Hatena Blog","title":"\u7c73\u56fd: \u30d5\u30a1\u30a4\u30b6\u30fc\u793e\u3068Allele\u793e\u304cCOVID-19\u30ef\u30af\u30c1\u30f3\u958b\u767a\u3067\u306e\u30ea\u30b5\u30fc\u30c1\u30c4\u30fc\u30eb\u4f7f\u7528\u306b\u304a\u3051\u308b\u7279\u8a31\u4fc2\u4e89\u3067\u548c\u89e3","author_url":"https://blog.hatena.ne.jp/kyoshinhei/","blog_url":"https://www.patent-topics-explorer.com/","categories":["\u7279\u8a31","\u7c73\u56fd","Bolar Exemption"],"author_name":"kyoshinhei","published":"2022-01-08 00:54:18","width":"100%","description":"\u30d5\u30a1\u30a4\u30b6\u30fc\u793e\u304c\u5c0e\u5165\u3057\u305fCOVID-19\u30ef\u30af\u30c1\u30f3\u306e\u958b\u767a\u3067Allele\u793e\u306e\u7279\u8a31\u3067\u4fdd\u8b77\u3055\u308c\u305f\u30ea\u30b5\u30fc\u30c1\u30c4\u30fc\u30eb\u3092\u4f7f\u7528\u3057\u3066\u3044\u305f\u3068\u3057\u3066\u3001Allele\u793e\u304c\u30d5\u30a1\u30a4\u30b6\u30fc\u793e\u7b49\u306b\u7279\u8a31\u4fb5\u5bb3\u8a34\u8a1f\u3092\u63d0\u8d77\u3057\u3066\u3044\u307e\u3057\u305f\u304c\u3001\u548c\u89e3\u304c\u6210\u7acb\u3057\u305f\u305d\u3046\u3067\u3059\u3002 Pfizer, biotech firm end patent fight over COVID-19 vaccine | Reuters \u306a\u304a\u3001\u30ab\u30ea\u30d5\u30a9\u30eb\u30cb\u30a2\u5357\u90e8\u5730\u533a\u9023\u90a6\u5730\u65b9\u88c1\u5224\u6240\u306b\u304a\u3044\u3066\u3001Allele\u793e\u306e\u7279\u8a31\u3067\u4fdd\u8b77\u3055\u308c\u305f\u30ea\u30b5\u30fc\u30c1\u30c4\u30fc\u30eb\u306e\u4f7f\u7528\u306f\u3001Bolar Exemption\u306e\u9069\u7528\u306f\u306a\u3044\u65e8\u306e\u5224\u65ad\u304c\u51fa\u3055\u308c\u3066\u3044\u305f\u3088\u3046\u3067\u3059\u3002 Allele Biotechnology and Pharma\u2026","url":"https://www.patent-topics-explorer.com/entry/2022/01/08/005418"}